BioTuesdays

Category - Feature

Feature

In conversation with Steve Damon

By Len Zehr As president, CEO and a co-founder of closely-held 4P Therapeutics, a leading developer of transdermal patches, Steve Damon cut his teeth in the sector at Altea Therapeutics and Durect. He was responsible...

February 24, 2015
Feature

Neovasc launching Reducer in Europe for RA

Neovasc (NASDAQ:NVCN; TSX:NVC) has begun an initial launch in Europe to introduce its implantable Reducer medical device for the treatment of refractory angina (RA) in advanced-stage cardiovascular patients. Alexei...

February 17, 2015
Feature

In conversation with David Giljohann

By Len Zehr As CEO of closely-held AuraSense Therapeutics, Dr. David Giljohann is one of the original inventors of the company’s technology for first-in-class therapies based on its proprietary spherical nucleic acid...

February 10, 2015
Feature

Dipexium advancing EU approval strategy for Locilex

By Len Zehr With its Phase 3 program underway in the U.S., Dipexium (NASDAQ:DPRX) has begun the regulatory process with the European Medicines Agency (EMA) for its Locilex topical treatment for diabetic foot infections...

February 3, 2015
Feature

In conversation with Allen Krantz

By Len Zehr As the founder, president and CEO of Advanced Proteome Therapeutics (TSX-V:APC; Frankfurt:OE8), Dr. Allen Krantz has successfully transitioned a career in academia to the biotech sector. From 1968 to 1974...

January 27, 2015
Feature

EndyMed expands sales effort in U.S.

By Len Zehr After five years of selling its skin rejuvenation devices to medical professionals through a distributor, EndyMed Medical (TASE:ENDY) has launched a U.S.-based direct sales operation through subsidiary...

January 20, 2015
Feature

Season’s Greetings (and JPM 2015)

Wow! What a great year 2014 turned out to be! On behalf of everyone at BioTuesdays, I would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and friends, we will...

December 19, 2014
Feature

Nuvo Research to release Phase 2 WF10 data in Q1

By Len Zehr Nuvo Research (TSX:NRI) plans to release, in the first quarter of 2015, the results of a confirmatory Phase 2 study for a potential blockbuster allergic rhinitis drug, WF10, which could be a game-changing...

December 2, 2014